Peering Into Insulet's Recent Short Interest
Short Stock Ideas From Each Sector With Earnings Quality in the Bottom 20%
Dow Hits Another Record, Core PCE 2.8% as Expected | Live Stock
S&P 500, Dow Hit Records, Trump Tariffs to Cost Hundreds of Billions | Wall Street Today
Unpacking the Latest Options Trading Trends in Intuitive Surgical
Intuitive Surgical Analyst Ratings
Dow Falls After Record, Trump Talks Tariffs on Day One | Live Stock
What's Going On With Hims & Hers Health Stock Monday?
Hims & Hers Health Trading 22% Higher, WIth Gains Attributed to FDA Nominee
After Trump's nomination of the FDA director, the supplier of "affordable weight loss drugs" Hims & hers surged more than 20%, reaching a historic high.
"Affordable weight loss pharmaceutical" supplier Hims & hers once rose over 20%, reaching $30.57, surpassing the previous intraday record high of $30.44 set on November 13. The reason is that institutions Hunterbrook Media, who benchmark against short sellers Citron, believe that Trump's nomination of Marty Makary as the director of the usa Food and Drug Administration (FDA) could benefit Hims & hers.
JPMorgan Updates Its U.S. Analyst Focus List – Adds TPR, ALRM, REG
Hims & Hers up 18% Amid Optimism for Compounders With Makary FDA Pick
BridgeBio Pharma, Rigetti Computing, Bath & Body Works And Other Big Stocks Moving Higher On Monday
S&P 500, Dow Hit Records Right After Open | Live Stock
Applied Digital And Hims & Hers Health Are Among Top 9 Mid-Cap Gainers Last Week (Nov 18-Nov 22): Are The Others In Your Portfolio?
Weekly Buzz: Nvidia Falls on Near Perfect Report, but Only For a Day
Breaking Down Masimo: 5 Analysts Share Their Views
Market Climbs, Bitcoin Close to $100k | Live Stock
Masimo Analyst Ratings
Shares Of Hims & Hers Health See Volume; Traders Circulate Court Filing Regarding Shortage Of Lilly's Tirzepatide Shortage, Parties Agree To Maintain Stay As Ordered By Court In October 2024, With Joint Status Report Due By December 19, 2024, Or...